ClinicalTrials.gg
CompletedNCT01555541Updated Jun 29, 2022Results posted

Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of Ofatumumab and Etoposide in Diffuse Large Cell Lymphoma Relapsed/Refractory, sponsored by C. Babis Andreadis. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-29.

Primary conditionLymphomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by C. Babis Andreadis · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing ofatumumab in Lymphoma — none open to participants now, none under way, none of them phase 3. ofatumumab · Lymphoma.

Enrollment
9th of 14
19 · median 33
Started
2012
with 2 others
Phase 2
11 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
C. Babis Andreadis

Among the 14 studies testing ofatumumab in Lymphoma, this one is the 9th largest by enrollment, is one of 3 that started in 2012, is one of 11 in phase 2, and was the 12th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 14 studies testing ofatumumab in Lymphoma is open now. The open studies under Lymphoma, anywhere →

Where they have run

About ofatumumab

ofatumumab: first FDA approval 2009 (KESIMPTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing ofatumumab in Lymphoma as a file.
02

Study summary

The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell transplantation (autoSCT) and to examine its effectiveness in eliminating residual diffuse large B-Cell Lymphoma (DLBCL) in patients.

Read the detailed description

Patients with relapsed Diffuse Large B-cell Lymphoma (DLBCL) who are refractory to or relapse within 12 months of first-line rituximab-based therapy, have poor outcomes with conventional approaches to autologous stem cell transplantation as detailed above. The investigators hypothesize that the intensive mobilization strategy developed can overcome some of the obstacles to successful autologous stem cell transplantation (ASCT) by both eliminating residual disease following salvage therapy and by facilitating stem cell collection. Even though there is clinical experience in the cooperative group setting with intensive pre-ASCT mobilization, it has never been prospectively validated in DLBCL and concerns exist as to its ability to improve outcomes with ASCT in this high-risk, and heavily pretreated group of patients. Furthermore, most patients in the study site's registry treated with intensive mobilization were rituximab-naïve and the findings may not translate in the rituximab-refractory population. The investigators also believe that ofatumumab, a novel monoclonal antibody against a distinct cluster of differentiation antigen 20 (CD20) epitope may in fact overcome rituximab resistance in DLBCL patients and through more effective complement dependent cytotoxicity (CDC) may eliminate minimal residual disease in the patient and contaminating tumor cells in the stem cell graft.

General Design

This is a single-institution, single-arm, prospective phase II study. Patients with high-risk DLBCL (defined as either achieving less than complete remission (CR) to initial rituximab-containing therapy or relapsing within 12 months of initial therapy) will be enrolled on this study and will undergo staging prior to receiving intensive mobilization with ofatumumab, etoposide, and high-dose ara-C (OVA). Following successful stem cell collection, patients will proceed to standard autologous transplantation with cyclophosphamide, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and etoposide (CBV) preparative regimen. Response evaluation will occur after salvage therapy, following intensive mobilization therapy (d42), at day +90 after ASCT, and at 6, 12 and 24 months thereafter. Event-free, progression-free, and overall survival will also be assessed until 48 months. The primary study endpoint is mobilization-adjusted complete metabolic response rate (maCR) following OVA. Subjects who are not chemosensitive to salvage therapy (i.e. do not achieve a partial response or complete response) will be re-evaluated after an additional salvage regimen. If they are still not chemosensitive at this point, they will be withdrawn from the study and replaced.

03

Conditions studied

  • Diffuse Large Cell Lymphoma Relapsed/Refractory

Browse trials for

Keywords

  • relapsed
  • refractory
  • DLBCL
  • lymphoma
  • B-cell
  • diffuse
04

In context

Lymphoma Reclassified

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

This study's enrollment of 19 is below the median of 43 across 2,320 interventional studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

C. Babis Andreadis is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of or relapsed -proven CD20+ diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma.
  • Age 18 years or older
  • Refractory to or relapse following a rituximab/anthracycline regimen
  • High-risk disease as defined by one of the following:

    • First relapse after CR within 12 months of initiation of front-line therapy
    • Less than CR to front-line therapy
    • Second-line age-adjusted International Prognostic Index score (sAAIPI) of 1 or higher at the time of relapse
  • Receipt of no more than three prior chemotherapy regimens. Monoclonal antibody therapy alone and involved field radiotherapy are not included in this number. Prior use of ofatumumab is allowed if there has been no disease progression following that therapy (i.e. ofatumumab-based salvage regimens are allowed)
  • (ECOG) performance status ≤ 2.

Eligibility to proceed to OVA

  • Chemosensitive disease as defined by at least a partial response to salvage therapy by positron emission tomography/computed tomography (PET/CT) criteria.
  • Bone marrow with less than 15% lymphoma cells following salvage therapy. No evidence of myelodysplasia.
  • Patients must have adequate organ function with serum creatinine \<2.0 mg/dL, total ≤2 times the (ULN), and (AST) ≤3 times the ULN.
  • Neutrophils >1,000/μL and >100,000/μL prior to day 0
  • No active uncontrolled infection.

Eligibility to proceed to CBV

  • Patients must be out of the hospital after OVA for a minimum of 4 weeks.
  • Adequate peripheral blood stem cell collection with cluster of differentiation 34 (CD34) cell dose ≥2 X 106 /kg (actual body weight).
  • No evidence of disease progression on day 42 assessment
  • Approved by the University of California, San Francisco (UCSF) Bone Marrow Transplant Committee to proceed with ASCT.

Exclusion criteria

Exclusion Criteria

  • Presence of disease transformation from a previously diagnosed low-grade lymphoma
  • Progression following prior ofatumumab-based therapy
  • Active central nervous system or meningeal involvement by lymphoma. Patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast MRI imaging for at least 3 months prior to study entry.
  • Evidence of myelodysplasia on any bone marrow .
  • Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half-lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study.
  • Other past or current . Subjects who have been free of malignancy for at least 3 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.
  • Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active .
  • History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
  • Known infection
  • cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure ( III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities.
  • Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient.
  • Positive serology for (HB) defined as a positive test for HbsAg and a detectable hepatitis B virus (HBV) DNA viral load. If negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HBV DNA test will be performed and if positive the subject will be excluded. If HBV DNA is negative, subject may be included but must undergo at least every 2-month HBV DNA polymerase chain reaction (PCR) testing from the start of treatment during the treatment course. Prophylactic antiviral therapy may be initiated at the discretion of the investigator.
  • Positive serology for hepatitis C (HC) defined as a positive test for hepatitis C antibody (HCAb), in which case reflexively perform a hepatitis C virus (HCV) PCR to confirm the result
  • Pregnant or lactating women. Women of must have a negative pregnancy test at screening.
  • Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence.
  • Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
  • Subjects who have received within the 4 weeks prior to planned initiation of study treatment.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Single-arm study

    Drug: Ofatumumab · Drug: Etoposide · Drug: Cytarabine

Interventions

  • 1000 mg IV days 0, 7, 14, 21

    Also known as: Arzerra, GSK1841157, HuMax-CD20

  • 10 mg/Kg IV over 24 hours daily, days 1-4

    Also known as: Vespid®, VP-16

  • 2000 mg/m2 IV twice daily, days 1-4

    Also known as: Cytosar-U®, Ara-C, Cytosine arabinoside

07

What researchers measure

Primary outcomes

  1. Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization

    CR will be calculated based on the PET/CT scan following 2 cycles of salvage therapy using the revised International Working Group (IWG) Criteria for a lymphoma response. This includes: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy, Post-treatment residual mass of any size is permitted as long as it is PET-, Spleen and/or liver, if enlarged before therapy based on physical exam or CT scan, should not be palpable on physical exam and should be considered normal size by imaging studies, and nodules related to lymphoma should disappear, If bone marrow was involved by lymphoma before treatment, infiltrate must have cleared on repeat bone marrow biopsy. Biopsy sample must be adequate (with goal of \> 20 mm unilateral core). If sample is indeterminate by morphology, it should be negative by immunohistochemistry. A sample that is negative by immunohistochemistry but demonstrates small population of clonal l

    Time frame: Day 42

  2. Number of Patients Achieving Mobilization-adjusted Complete Response (maCR)

    Number of patients achieving maCR to the treatment upon successful stem cell mobilization, defined as at least 2 x10\^6 cluster of differentiation 34 (CD34)+cells/Kg of actual body weight. Patients who require use of plerixafor or an autologous bone marrow harvest are considered mobilization failures and will be treated as non-responders.

    Time frame: Day 42

Secondary outcomes

  1. Number of Patients Who Received OVA and Then Met Criteria to Proceed to ASCT and Achieved a CR/Partial Response (PR) Post-ASCT

    Determination of CR or PR must meet the revised International Working Group (IWG) Criteria for lymphoma response

    Time frame: Up to 5 months

  2. Number of Patients Who Advance From Partial Response (PR) to Complete (CR)

    Fluorodeoxyglucose-positron emission tomography (FDG-PET) conversion rate was used determined the number of participants who improved following OVA Treatment.

    Time frame: Up to 5 months

  3. Number of Participants With Successful Neutrophil Engraftments

    Neutrophil engraftment is defined as the first day of 3 consecutive days with absolute neutrophil count of \>500 cells/microlitre (uL). Response evaluation will occur at day +90 after ASCT, and at 6, 12 and 24 months thereafter

    Time frame: Up to 24 months after ASCT

  4. Number of Participants With Successful Platelet Engraftments

    Platelet engraftment is defined as the first of three consecutive measurements for which the platelet count was \> 20,000/uL, and must be at least 24 hours following the last platelet transfusion. Response evaluation will occur at day +90 after ASCT, and at 6, 12 and 24 months after ASCT

    Time frame: Up to 24 months after ASCT

  5. Median Time to Progression

    Time to progression (TTP) is defined as the time from treatment after OVA until documented lymphoma progression or receipt of anti-lymphoma therapy (except for planned post-ASCT radiotherapy) or death due to lymphoma. Patients are to be censored at the time of last followup or death due to another cause

    Time frame: Up to 48 months

  6. Progression Free Survival Rate

    The percentage of participants in the study still alive at time of censoring. The time frame defined as the time from day 0 of OVA treatment until lymphoma progression, receipt of anti-lymphoma therapy (except for planned post-ASCT radiotherapy), or death as a result of any cause. Patients will be censored at the time of median follow-up.

    Time frame: Up to 24 months

  7. Overall Survival Rate (OS)

    The percentage of participants in the study still alive at time of censoring. The time frame is defined as the time from day 0 of OVA treatment until death as a result of any cause. Patients will be censored at the time of last followup

    Time frame: Up to 24 months

08

Results

Posted May 17, 2019
Limitations and caveats
The study closed early due to low accrual

Participant flow

Salvage Response Assessment
Participant flow — Salvage Response Assessment
MilestoneTreatment
Started19
Completed19
Not completed0
OVA Treatment
Participant flow — OVA Treatment
MilestoneTreatment
Started19
Completed19
Not completed0
Autologous Stem Cell Transplantation
Participant flow — Autologous Stem Cell Transplantation
MilestoneTreatment
Started12
Completed12
Not completed0

Outcome measures

PrimaryNumber of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization

CR will be calculated based on the PET/CT scan following 2 cycles of salvage therapy using the revised International Working Group (IWG) Criteria for a lymphoma response. This includes: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy, Post-treatment residual mass of any size is permitted as long as it is PET-, Spleen and/or liver, if enlarged before therapy based on physical exam or CT scan, should not be palpable on physical exam and should be considered normal size by imaging studies, and nodules related to lymphoma should disappear, If bone marrow was involved by lymphoma before treatment, infiltrate must have cleared on repeat bone marrow biopsy. Biopsy sample must be adequate (with goal of \> 20 mm unilateral core). If sample is indeterminate by morphology, it should be negative by immunohistochemistry. A sample that is negative by immunohistochemistry but demonstrates small population of clonal l

Time frame:
Day 42
Reported as:
Count of participants · Participants
Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization
ParticipantsTreatment
Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization10
PrimaryNumber of Patients Achieving Mobilization-adjusted Complete Response (maCR)

Number of patients achieving maCR to the treatment upon successful stem cell mobilization, defined as at least 2 x10\^6 cluster of differentiation 34 (CD34)+cells/Kg of actual body weight. Patients who require use of plerixafor or an autologous bone marrow harvest are considered mobilization failures and will be treated as non-responders.

Time frame:
Day 42
Reported as:
Count of participants · Participants
Number of Patients Achieving Mobilization-adjusted Complete Response (maCR)
ParticipantsTreatment
Number of Patients Achieving Mobilization-adjusted Complete Response (maCR)10
SecondaryNumber of Patients Who Received OVA and Then Met Criteria to Proceed to ASCT and Achieved a CR/Partial Response (PR) Post-ASCT

Determination of CR or PR must meet the revised International Working Group (IWG) Criteria for lymphoma response

Time frame:
Up to 5 months
Reported as:
Count of participants · Participants
Number of Patients Who Received OVA and Then Met Criteria to Proceed to ASCT and Achieved a CR/Partial Response (PR) Post-ASCT
ParticipantsTreatment
Number of Patients Who Received OVA and Then Met Criteria to Proceed to ASCT and Achieved a CR/Partial Response (PR) Post-ASCT11
SecondaryNumber of Patients Who Advance From Partial Response (PR) to Complete (CR)

Fluorodeoxyglucose-positron emission tomography (FDG-PET) conversion rate was used determined the number of participants who improved following OVA Treatment.

Time frame:
Up to 5 months
Reported as:
Count of participants · Participants
Number of Patients Who Advance From Partial Response (PR) to Complete (CR)
ParticipantsTreatment
Number of Patients Who Advance From Partial Response (PR) to Complete (CR)2
SecondaryNumber of Participants With Successful Neutrophil Engraftments

Neutrophil engraftment is defined as the first day of 3 consecutive days with absolute neutrophil count of \>500 cells/microlitre (uL). Response evaluation will occur at day +90 after ASCT, and at 6, 12 and 24 months thereafter

Time frame:
Up to 24 months after ASCT
Reported as:
Number · participants
Number of Participants With Successful Neutrophil Engraftments
participantsTreatment
Number of Participants With Successful Neutrophil Engraftments12
SecondaryNumber of Participants With Successful Platelet Engraftments

Platelet engraftment is defined as the first of three consecutive measurements for which the platelet count was \> 20,000/uL, and must be at least 24 hours following the last platelet transfusion. Response evaluation will occur at day +90 after ASCT, and at 6, 12 and 24 months after ASCT

Time frame:
Up to 24 months after ASCT
Reported as:
Number · participants
Number of Participants With Successful Platelet Engraftments
participantsTreatment
Number of Participants With Successful Platelet Engraftments12
SecondaryMedian Time to Progression

Time to progression (TTP) is defined as the time from treatment after OVA until documented lymphoma progression or receipt of anti-lymphoma therapy (except for planned post-ASCT radiotherapy) or death due to lymphoma. Patients are to be censored at the time of last followup or death due to another cause

Time frame:
Up to 48 months
Reported as:
Median · months
Median Time to Progression
monthsTreatment
Median Time to Progression13.2 (1.4 to 48)
SecondaryProgression Free Survival Rate

The percentage of participants in the study still alive at time of censoring. The time frame defined as the time from day 0 of OVA treatment until lymphoma progression, receipt of anti-lymphoma therapy (except for planned post-ASCT radiotherapy), or death as a result of any cause. Patients will be censored at the time of median follow-up.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Progression Free Survival Rate
percentage of participantsTreatment
Progression Free Survival Rate47 (24 to 67)
SecondaryOverall Survival Rate (OS)

The percentage of participants in the study still alive at time of censoring. The time frame is defined as the time from day 0 of OVA treatment until death as a result of any cause. Patients will be censored at the time of last followup

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Overall Survival Rate (OS)
percentage of participantsTreatment
Overall Survival Rate (OS)59 (33 to 78)

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment3/19 (15.8%)4/19 (21.1%)9/19 (47.4%)
Most frequent serious events
Most frequent serious events
EventTreatment
Anal PainGastrointestinal disorders1/19
PneumonitisRespiratory, thoracic and mediastinal disorders1/19
SepsisInfections and infestations1/19
Allergic reactionImmune system disorders1/19
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTreatment
Platelet count decreasedInvestigations9/19
Neutrophil count decreasedInvestigations8/19
Febrile neutropeniaBlood and lymphatic system disorders5/19
White blood cell decreasedInvestigations4/19
Mucositis oralGastrointestinal disorders4/19
AnemiaBlood and lymphatic system disorders3/19
DiarrheaGastrointestinal disorders3/19
NauseaGastrointestinal disorders3/19
VomitingGastrointestinal disorders2/19
Infections and infestations - OtherInfections and infestations2/19

Baseline characteristics

Age, Customized
Age, Customized(Participants)Treatment
20-29 years1
30-39 years1
40-49 years4
50-59 years7
60-69 years6
Sex: Female, Male
Sex: Female, Male(Participants)Treatment
Female7
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment
Hispanic or Latino4
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race1
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)Treatment
United States19
Cancer Stage at Diagnosis
Cancer Stage at Diagnosis(Participants)Treatment
Stage I - II5
Stage III - IV14
09

Study locations

1 site
  • University of California, San Francisco
    San Francisco, California 94143, United States
10

References and documents

Publications

  • Thiruvengadam SK, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T 3rd, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):246-256.e2. doi: 10.1016/j.clml.2020.11.005. Epub 2020 Nov 11. PubMed 33288485 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Jul 2017, 61 months.

Results were first posted in May 2019, 1 year 10 months after primary completion.

Of 237 non-industry phase 2 interventional studies under Lymphoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 114. This study's 61 months is close to that.

Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 15, 2012
StartActual
May 25, 2012
Primary completionActual
Jul 6, 2017
CompletionActual
Jul 1, 2021
Results first posted
May 17, 2019
Last update
Jun 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01555541
Lead sponsor
C. Babis Andreadis
Responsible party
C. Babis Andreadis (Assistant Clinical Professor, Department of Medicine, University of California, San Francisco) — Sponsor-investigator
First posted
Mar 15, 2012
Start date
May 25, 2012
Primary completion
Jul 6, 2017
Completion
Jul 1, 2021
Results posted
May 17, 2019
Last update
Jun 29, 2022

Study contacts

Charalambos Andreadis, MD, MSCE
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ofatumumab · Etoposide · Cytarabine

Start the discussion